News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ArQule, Inc. Enrolls First Patient in Phase 1 Trial of ARQ 736, Its Pan-RAF Inhibitor
December 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
March 4, 2026
·
3 min read
·
Jennifer Smith-Parker
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
March 3, 2026
·
1 min read
·
BioSpace Insights
Gene therapy
Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold
March 3, 2026
·
2 min read
·
Tristan Manalac
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
·
3 min read
·
Heather McKenzie
